IRB #

IRB00012012

Title

A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy In Patients With Completely Resected STAGE IB−IIIA Non-Small Cell Lung Cancer

Principal Investigator

Khaled Tolba

Study Purpose

To study the efficacy and safety of the study drug. The study drug Atezolizumab is an antibody that targets PD-L1. It will be compared to FDA approved drugs that are used with non small cell lung cancer.

Medical Condition(s)

Non small cell lung cancer

Eligibility Criteria

18 years of age and older
ECOG status of 0 or 1

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Study treatment could last up to 2 years.
Participants that agree to follow up could potentially be followed for 1 year or the rest of their life, depending on which treatment they receive.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

F. Hoffmann-La Roche Ltd

Recruitment End

07/13/2020

Compensation Provided

No


Go Back